Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...
Read Full NewsLong-acting injectable antipsychotics are linked to lower rehospitalization rates than oral antipsychotics in patients with bipolar I disorder, a study shows.
The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.
1.
For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.
2.
Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.
3.
Survival is extended by a new treatment option for metastatic colorectal cancer.
4.
Three out of ten breast cancers detected between screenings, study finds
5.
Basal stem-like cells identified as origin of small cell lung cancer in lab models
1.
The Miracle of Thyrogen Injection: A New Hope for Thyroid Cancer Treatment
2.
Radiation Oncology: Integrating AI, Theranostics, and Adaptive Therapies for Personalized Cancer Care
3.
Exploring the Mysteries of Myxoma: A New Frontier in Medical Research
4.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
5.
Landmark Medical Oncology Trials Redefining Early Breast Cancer Management
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
3.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
5.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge